AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

AstraZeneca's new drug, baxdrostat, has successfully lowered blood pressure in a late-stage trial for treatment-resistant ...

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...